Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Fosaprepitant Triple Therapy for PONV Prevention
NCT04853147Phase 3Completed
- Sponsor
- The Sixth Affiliated Hospital of Sun Yat-Sen University
- Start
- Apr 2021
- Primary completion
- Apr 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of fosaprepitant in postoperative nausea and vomiting (PONV) (2 arms), sponsored by The Sixth Affiliated Hospital of Sun Yat-Sen University. Primary endpoint: Proportion of participants with PONV during the first 24 postoperative hours at 24 hours. Started Apr 2021; status: completed.
02
Drugs
fosaprepitant
03
Conditions
postoperative nausea and vomiting (PONV)
Beyond the preview
Go deeper on NCT04853147.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04853147.